David B. Weiner

This paper introduces cTACs, synthetic molecules that degrade PD-L1 across immune and tumor cells, enhancing T cell activation and tumor suppression in vivo.

This study shows Notch2 signaling enhances TLR3 and TLR4 responsiveness in MZ B cells, promoting immune responses to viral and bacterial pathogens.

The paper shows that a drug holiday during PD-1 blockade improves reinvigoration of exhausted T cells by restoring progenitor cell function and reducing adaptive resistance.

The paper identifies frequent and genetically diverse CDRH3 topologies in the human antibody repertoire that can be targeted by vaccination to elicit broadly neutralizing antibodies.

This study shows targeting the LxCxE cleft pocket of Rb in M2 macrophages inhibits ovarian cancer progression by reducing immunosuppressive TAMs and enhancing T cell infiltration.

This paper introduces WIN332, an engineered immunogen that elicits N332-glycan-independent V3-glycan antibodies in nonhuman primates after a single immunization.

This paper identifies engineered transfer RNAs (ACE-tRNA) that suppress premature termination codons in mammalian cells and mice, showing high suppression activity for common disease-causing nonsense codons.